Last reviewed · How we verify
FBA-A20FMDV2
At a glance
| Generic name | FBA-A20FMDV2 |
|---|---|
| Modality | Recombinant protein |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6 (NA)
- IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types (NA)
- Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging (PHASE1)
- A Validation and Dosimetry Study of GSK2634673F PET Ligand (PHASE1)
- First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FBA-A20FMDV2 CI brief — competitive landscape report
- FBA-A20FMDV2 updates RSS · CI watch RSS